久方生技 7608 股份有限公司

25/09/2025

Maxima Biotech, Developer of World’s No. 2 Cordless Surgical Scalpel, Unveils Global B2B Strategy at PwC Taiwan Event

TAIPEI, Taiwan – September 25, 2025 – Maxima Biotech Inc. (TPEx: 7608) today announced its global B2B strategy at a strategic matchmaking event hosted by PwC Taiwan and the Taipei Exchange (TPEx). The move addresses the growing global demand for supply chain resilience by positioning essential medical devices as strategic national assets.

​Leveraging its proven direct-to-consumer (B2C) model in Taiwan, Maxima Biotech is now offering a turnkey solution for the US$10 billion advanced energy-based surgical device market.

​Key Highlights:
​Proven Model: Successfully validated a B2C business model (MVP) in the Taiwan home market.
​Top-Tier Technology: Its world’s 2nd cordless ultrasonic dissector has attracted active evaluation from major international corporations.
​Global Validation: Completed successful preclinical trials with international partners in California (2024).

​Maxima Biotech will further present its global strategy in a special session at MD&M West in 2026, themed "A Turnkey Solution for National Medical Device Autonomy."

​About Maxima Biotech Inc.
Maxima Biotech Inc. (TPEx: 7608) is a Taiwan-based medical technology company listed on the Go Incubation Board for Startup and Acceleration Firms (GISA) of the Taipei Exchange. The company specializes in developing advanced energy-based surgical devices to enhance surgical outcomes and promote medical autonomy worldwide.

22/09/2025

✈️ MEDICAL JAPAN TOKYOまで、あと7日！
​いよいよ来週、東京の幕張メッセで皆様とお会いできることを、MAXIMAチーム一同、心より楽しみにしております！台湾が誇る「世界で2番目のコードレス超音波メス」を国際的な舞台でご紹介できることに、今から胸を躍らせています。🔥
​会期中の貴重なお時間を最大限に活用するため、当社の革新技術や日本市場での協業にご興味をお持ちの方は、ぜひ事前の個別商談をご予約ください。
​以下のリンクから、ご希望の時間帯を確保し、当日はスムーズで中身の濃い情報交換をいたしましょう！
​👇 ご予約はこちらから：
https://calendly.com/tanghsiaowei-maximabio/maxima-taiwan-medical-japan
​東京でお会いしましょう！
🗓️ 会期： 10月1日(水)～3日(金)
📍 ブース番号： 23-14
​ #久方生技 #東京醫療展 #台灣之光 #創新醫療 #日本市場 #合作夥伴募集中 #幕張メッセ

17/09/2025

✨G Camp 前進東京✈️
我們將於 10 月帶領 4 間傑出的獲獎團隊 參加 2025 Medical Japan Tokyo 展會——日本最大規模的醫療綜合展之一！🎉
🏆 久方生技 7608 股份有限公司
🏆 威捷生物醫學股份有限公司
🏆 遠視界科技股份有限公司
🏆 擴核生醫科技股份有限公司
這四家來自台灣的優秀新創團隊，將在國際舞台上展示最新的醫療技術與創新解決方案，並與來自全球的醫療產業專家交流合作，探索更多可能。
📊 展會亮點：
超過 650 家參展商、18,000 名業界人士

涵蓋七大專區：醫療器械、長照與福利、感染防控、數位醫療轉型、藥局解決方案、診所設備，以及預防保健

📍 展會資訊：
🗓 2025年10月1日（三）～10月3日（五）
📌 千葉幕張國際展覽中心（Makuhari Messe, Chiba, Japan）
🔗 更多資訊：Medical Japan Tokyo 官方網站
誠摯邀請大家一同關注，支持臺灣醫療新創團隊，在國際舞台上綻放光芒！🚀

29/08/2025

日前(25)，專注開發無線超音波刀公司──久方生技(7608)在「2025GCamp國際創新創業訓練營」決賽中，從27組優秀團隊中脫穎而出，獲國際鏈結獎-MedicalJapan。政府將補助並輔導久方生技前進日本重要醫療展會MedicalJapan，為久方打開.....

28/08/2025

14/08/2025

久方生技（7608）為台灣高階微創手術器械領導者，專注解決手術能量器械的高價與供應鏈脆弱問題。核心產品「久方無線超音波手術刀」為全球第二款、台灣首款成功商品化的無線機種，具低煙霧、低熱傷與高度便利性，性能.....

02/06/2025

Taiwan's MedTech Sector Embraces Value Chain Innovation: A Strategic Blueprint for Global Leadership, Domestic Production, and Resilient Supply Chains

TAIPEI, TAIWAN – Jun 02, 2025 – Taiwan's MedTech industry is undergoing a pivotal transformation! Dr. Hsiao-Wei Tang, General Manager of Maxima Biotech Co., Ltd., recently delivered a keynote speech at the "2025 Taiwan International Medical Industry Delegation" hosted by the Overseas Community Affairs Council, dissecting the opportunities and strategic blueprint for MedTech innovation in Taiwan. He highlighted how Value Chain Innovation, rooted in Michael Porter's seminal theories, is driving the localization of high-value medical devices and the construction of robust supply chains.

Dr. Tang defined Value Chain Innovation as a systematic approach to integrating, optimizing, and innovating various internal business activities—from product R&D and manufacturing to supply chain management, marketing, and customer service—to create higher product or service value and enhance overall competitiveness. Drawing from Michael Porter's value chain framework, Dr. Tang explained that this approach allows companies to simultaneously pursue both cost leadership and differentiation. Taiwan, with its strengths in precision manufacturing and a highly efficient supply chain, can achieve cost advantages while differentiating through product and process innovation. He emphasized that in the current global climate, Taiwan's exceptional MedTech capabilities and strong ICT foundation enable a transition from contract manufacturing to a high-value "strategic partner".

Drawing on Maxima Biotech's experience, Dr. Tang illustrated how the company's commitment to "incremental innovation" has been a core success factor. Maxima Biotech strategically targets products with proven technology, strong market potential, and opportunities arising from patent cliff. This approach is guided by an agile "innovation optimization loop" (often seen as MVP → PMF → Pivot in startups), ensuring continuous alignment with clinical needs and maintaining a competitive edge. Maxima Biotech's competitive advantage lies in delivering product performance equivalent to leading global manufacturers, but at a more competitive cost, leveraging Taiwan's strengths in advanced manufacturing and cost-efficiency.

This practical application of Value Chain Innovation has yielded significant results: since its launch in 2022, Maxima Biotech's cordless ultrasonic dissector has been used in over 3,500 surgical cases in Taiwan and has successfully gained adoption in 80 hospitals, capturing over 10% of the market share.

Dr. Tang stated that Taiwan's MedTech industry already possesses innovative technology and manufacturing prowess, having validated a successful model of Value Chain Innovation. Looking ahead, Maxima Biotech will continue to deepen its presence in the Taiwanese market, translating accumulated clinical data into international promotion materials. Through diverse strategies such as "Niche Market Leadership," "Strategic Partnership", or "Turnkey Solutions," the company aims to accelerate international market expansion, maintaining technological leadership and competitive advantages.

"The global Taiwanese diaspora plays an irreplaceable and crucial role in the worldwide MedTech value chain," Dr. Hsiao-Wei Tang emphasized, highlighting their potential as partners for market expansion, connecting capital and technology, and building resilient supply chains globally.

30/04/2025

久方生技攜手伍斯特理工學院，產學合作深耕國際市場

[台灣台中] – [2025年4月28日] – 久方生技股份有限公司與美國伍斯特理工學院 (WPI) 展開策略合作，由 WPI 學生團隊在久方生技的指導下，針對其產品進行深入的專利風險評估，並協助制定全面的國際市場進入策略，以期在全球市場取得更強勁的競爭優勢。特別感謝國家科學及技術委員會促成WPI與台灣的專題合作，並於台灣設立課題研究中心，為本次合作奠定重要基礎。

成立於 1865 年的伍斯特理工學院Worcester Polytechnic Institute (WPI)是一所美國頂尖的私立研究型大學，以其在工程和科技領域的卓越表現聞名。WPI 提供超過 70 個科學、工程、技術、商業與管理、以及人文藝術等領域的學士、碩士和博士學位課程。WPI 強調專案導向學習，鼓勵學生透過實際專案和團隊合作來應用理論知識，培養批判性思維和實踐能力。WPI 在美國大學排名中名列前茅，例如在 US News & World Report 中位列前 80 名。WPI 在全球 31 個國家設有 50 多個課題研究中心。

此次 WPI 合作團隊由 Prof. Burrier 及 Prof. Hultquist 領軍，包含五位來自不同領域的三年級學生，展現 WPI 強調跨領域合作的精神。在久方生技的指導下，WPI 團隊將以實作方式學習，深入了解醫療器材產業的市場特性與專利布局策略。

久方生技說明其在進入國際市場的實務，引導 WPI 團隊進行包含市場評估、客戶策略與客戶心聲分析、競爭分析、客戶購買流程理解等深入的市場研究。同時，久方生技也指導WPI團隊針對現有專利，考量地區及市場、申請時間、技術深度及廣度等多個變項，進行專利監控及迴避設計，並參考Ove Granstrand教授提出的專利布局策略，擬定攻擊性專利策略與防禦性專利策略，並思考專利授權及技術商品化等多種專利運用方式。

透過久方生技的實務指導與 WPI 團隊的學術能量結合，此合作案不僅為久方生技帶來新的市場洞察與專利策略，更讓 WPI 學生團隊獲得寶貴的實作經驗。久方生技期望能透過這次產學合作，有效降低市場進入風險，並最大化市場拓展效益。

WPI 團隊已抵台展開為期七週的實地研究，初期會議已針對地理專利現狀分析及市場進入策略進行深入探討，並著手開發專利監控應用程式 (App) 以強化智財管理。團隊也於 4 月 24 日參訪久方中科研發中心，親身體驗其高階能量電刀的卓越性能。

久方生技致力於高階能量醫療器械的創新與製造，其國產無線超音波刀已通過 TFDA 認證，並在台灣累積逾 3500 例成功臨床案例。公司以普及微創手術為己任，期許提供更易於負擔且高品質的醫療方案。透過與 WPI 等國際學術機構的合作，久方生技不斷提升自身實力，為進軍全球市場奠定堅實基礎。WPI 團隊的最終研究成果將於 5 月 2 日在東吳大學公開發表。

25/04/2025

久方生技整合台灣優勢共創可用、可及、可負擔微創手術未來
Make Minimally Invasive Surgery Available, Accessible, and Affordable

台灣，台北 2025年4月25日 訊 – 在全球人口老化、醫療成本攀升及供應鏈重組的多重挑戰下，實現讓微創手術普及化Available、易於獲取Accessible、且價格可負擔Affordable的目標，已成為全球醫療創新的核心焦點。值此關鍵時刻，久方生技在Ircad Taiwan 秀傳亞洲遠距微創手術中心的多次安排下，與全球微創手術先驅 Prof. Jacques Marescaux交流，闡述公司如何承襲IRCAD的變革精神與臨床創新網絡，展示台灣已臻成熟的微創手術產業生態系，致力於將高品質微創手術醫材推向全球，加速臨床創新優化，並提出協助夥伴國家建立在地醫療韌性的前瞻模式。

IRCAD：加速外科典範轉移的革命性力量
傳統外科教育以一對一師徒制，難以應對微創手術等新技術的快速普及需求。由Prof. Jacques Marescaux創立的IRCAD網絡，以其系統化、規模化的教育平台及WebSurg等數位工具，將專家知識核心，高效輻射至全球學習者，徹底改變外科學習曲線，極大加速了微創手術的全球化進程。久方生技總經理湯孝威博士表示：「Marescaux教授對全球外科教育及MIS普及的貢獻是革命性的，其對全球人類的影響力堪稱諾貝爾獎級別。」

全球變局下的挑戰與台灣契機
全球醫材市場雖由老齡化及智慧醫療需求驅動成長，但也面臨嚴峻的醫療成本壓力與地緣政治風險。國際大廠在啟動美國製造的同時，也積極尋求具備可靠性與高品質的供應鏈夥伴，為技術領先的台灣CDMO廠商帶來新的策略合作契機。然而，關稅壁壘與供應鏈不確定性，也迫使台灣產業必須憑藉持續的技術創新與極致的營運效率，積極開拓包括美國在內的全球多元市場。

久方生技：整合創新，提供高性價比解決方案
在此變局中，久方生技精準定位於提供國際大廠質量，更具成本競爭力的醫材。公司自創立初期即獲『非佳不可』Qisda 佳世達科技 醫療大艦隊的全力支持，運用台灣在資通訊 ICT 與精密製造的深厚實力，專注於高技術門檻的微創手術能量器械。
「我們的核心策略是建立一個從臨床需求洞察到高效製造的『創新迴圈』。」湯博士解釋道。「透過與臨床醫師的緊密連結，我們將第一線回饋迅速導入研發與生產，實現敏捷開發與持續優化。」目前，久方生技的無線超音波刀已獲TFDA核准，在台灣逾80家醫院累積超過3500例手術實績，充分驗證了產品的臨床信賴度與市場潛力，並運用「乙組冠軍策略」進軍國際市場。

策略夥伴關係：實踐「小幫手策略」與共創價值
為加速創新落地與拓展全球市場，久方生技積極尋求與國際領導企業建立互補的策略夥伴關係，這即是公司的「小幫手策略」核心。與IRCAD Taiwan的緊密合作便是此策略的關鍵實踐：這不僅加速了久方對於前沿臨床需求的洞察與創新醫材的實現，更能運用IRCAD無可比擬的全球網絡與教育平台，對創新概念與產品進行快速驗證和優化。透過此合作模式所產生的關鍵智慧財產權 IP 與臨床數據 Data，將為久方生技尋求與國際大廠進行更深層次的技術合作或市場授權，奠定極為重要的基礎。

「整廠輸出」：賦能夥伴，共建在地醫療韌性
面對世界各國將醫療供應鏈視為國家安全戰略的高度重視，久方生技正將其在台灣驗證成功的整合模式，發展為可複製、可輸出的解決方案。「我們正積極探索『整廠輸出』Turnkey Solution 的合作模式，」湯博士表示，「在全球化面臨挑戰、貿易壁壘升高的時代，協助有意願的國家建立自主、高品質且具成本效益的必要醫材供應鏈，不僅是對地緣政治風險的回應，更是強化全球健康體系韌性、實現醫療在地化的具體路徑。」

展望未來：從代工走向策略夥伴
在全球結構重組趨勢下，台灣醫材產業需從傳統代工模式，轉型為具備高附加價值的策略夥伴。久方生技將持續強化高值創新、深化臨床鏈結、打造智慧韌性供應鏈。

湯博士總結：「結合IRCAD的全球影響力與台灣的產業優勢，久方生技致力於提供高品質、可負擔的微創手術解決方案，我們採取的『乙組冠軍策略』，目標是成為國際品牌之外，最具領導性的高價值選項；同時，我們也透過實踐『小幫手策略』，與IRCAD Taiwan的深度合作，積極尋求與國際大廠互補的策略性合作機會。最終，我們更期望透過『整廠輸出』模式賦能全球夥伴，共同為實現微創手術普及化Available、易於獲取Accessible、且價格可負擔Affordable的目標貢獻力量，提升全人類的健康福祉。」

22/04/2025

FOR IMMEDIATE RELEASE

Maxima Biotech Completes PwC Taiwan Accelerator, Unveils Growth Strategy and Market Impact at Demo Day

TAIPEI, Taiwan – April 23, 2025 – Maxima Biotech Inc., a leading innovator in advanced surgical energy devices, today announced the successful completion of the PwC Taiwan Entrepreneur Growth Accelerator Scale Programme. Over the past six months, Maxima Biotech received tailored strategic guidance and comprehensive support from PwC, accelerating the company’s transformation and market expansion.

This partnership enabled Maxima Biotech to sharpen its growth strategy, optimize operations, and deepen engagement with industry partners and capital markets.

At today’s Demo Day, Dr. Tom Tang, PhD, CEO of Maxima Biotech, presented the company’s strategic vision. He highlighted how Maxima Biotech leverages Taiwan’s technological strengths and clinical expertise to carve out a unique position in the global medical device market. The company’s focus is on advanced surgical energy devices, delivering world-class technology with Taiwan’s renowned cost efficiency and innovative agility.

“We are committed to empowering clinicians with advanced surgical tools—akin to the legendary ‘Heavenly Sword’ and ‘Dragon Slaying Saber’—renowned for their unmatched performance,” said Dr. Tang. “By closely integrating with Taiwan’s robust supply chain and incorporating real-world surgeon feedback, we accelerate product innovation and maintain a sharp competitive edge.”

Since launching its flagship Cordless Ultrasonic Dissector in 2022, Maxima Biotech’s devices have been rapidly adopted in 80 hospitals across Taiwan, supporting over 3,500 surgical cases. Building on this momentum, the company is set to introduce the world’s second Curved Jaw Cordless Ultrasonic Dissector, further expanding its portfolio of advanced surgical solutions.

Maxima Biotech’s mission is to translate Taiwan’s technological and medical strengths into high-value medical devices that benefit patients worldwide. By harnessing local innovation and operating as a strategic hub for cost-effective production and Asian distribution, the company aims to address significant unmet clinical needs on a global scale.

Reflecting on the accelerator experience, Dr. Tang remarked, “The PwC Taiwan Scale Programme has been instrumental for Maxima Biotech. The exceptional support and resources provided critical guidance and strengthened our industry connections at a pivotal stage. We are grateful for PwC’s partnership and excited for the next phase of innovation and global expansion.”

About Maxima Biotech Inc.
Maxima Biotech Inc. is a Taiwanese leader in advanced surgical energy devices, recognized for rapid product development, strong clinical adoption, and scalable, cost-effective manufacturing. The company’s portfolio features the world’s second cordless ultrasonic dissector and a pipeline of minimally invasive solutions. Maxima Biotech delivers agile R&D, OEM/ODM collaboration, and robust supply chain integration from its strategic Asia hub.

13/02/2025

MAXIMA Biotech Joins Flinders University's Work Integrated Learning Program

MAXIMA Biotech (7608) is thrilled to announce its successful collaboration with Flinders University's Work Integrated Learning (WIL) program. Over an enriching 20-week internship, we had the privilege of hosting two exceptional students, Jonas and Joanne, whose enthusiasm and dedication brought immense value to our organization.
During their internship, Jonas and Joanne gained practical insights into the medical device industry through a variety of activities, including:
-Observing Advanced R&D Processes: The students immersed themselves in the complete research and development cycle of cutting-edge medical devices at MAXIMA Biotech.
-Regulatory and Clinical Data Analysis: They actively participated in collecting and analyzing regulatory and clinical data, deepening their understanding of compliance and evidence-based practices.
-Studying Biodesign Principles: Through an in-depth exploration of Biodesign: The Process of Innovating Medical Technologies, they learned how to conceptualize and develop medical innovations. Additionally, they contributed to the creation of three specialized lectures on medical device innovation.

This collaboration offered Jonas and Joanne invaluable hands-on experience in Taiwan's rapidly growing medical device sector. At the same time, partnering with Flinders University strengthened MAXIMA Biotech's innovation processes and enhanced its international visibility.

We firmly believe that academic-industry partnerships like this are essential for fostering cross-disciplinary talent capable of driving innovation in the global medical device industry.
MAXIMA Biotech looks forward to continuing these meaningful collaborations to nurture talent and contribute to the growth of the medical device sector worldwide. We extend our heartfelt gratitude to Jonas, Joanne, and Flinders University for making this partnership a remarkable success.